Loading
Precemtabart tocentecan is an experimental antibody-drug conjugate from EMD Serono Research & Development Institute in phase 3 trials for colorectal cancer, aimed at CEACAM5.
Precemtabart tocentecan is an antibody-drug conjugate developed by EMD Serono Research & Development Institute. Its target is CEACAM5 (the sponsor names CEACAM5). The sponsor states: An antibody-drug conjugate against CEACAM5 carrying an exatecan (topoisomerase inhibitor) payload, given intravenously once every three weeks. ClinicalTrials.gov describes the intervention as: Precem-TcT, administered, once every 3 weeks intravenously, on Day 1 of each 21-day cycle. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT07549412 (A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)), in colorectal cancer. The largest, NCT07549412, plans to enrol 1020 participants with primary completion expected 2029-10-16. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.
An antibody-drug conjugate against CEACAM5 carrying an exatecan (topoisomerase inhibitor) payload, given intravenously once every three weeks. Connects to CEACAM5.
1.Precemtabart tocentecan's antibody arm binds CEACAM5 on the surface of the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Precemtabart tocentecan" OR ABSTRACT:"Precemtabart tocentecan" OR TITLE:"Precem-TcT" OR ABSTRACT:"Precem-TcT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Precemtabart tocentecan, not a curated reading list.
Shares CEACAM5, Colorectal cancer and the tag pipeline.
Shares CEACAM5, Colorectal cancer and the tag pipeline.
Shares CEACAM5, Colorectal cancer and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares Merck KGaA (EMD Serono) and the tag pipeline.
Shares CEACAM5 and the tag pipeline.
Shares Colorectal cancer and the tag pipeline.